Oculis Holding AG (NASDAQ:OCS) Short Interest Update

Oculis Holding AG (NASDAQ:OCS) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 24,300 shares, an increase of 54.8% from the October 31st total of 15,700 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 49,800 shares, the days-to-cover ratio is presently 0.5 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Oculis in a research report on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $29.20.

Oculis Price Performance

Shares of NASDAQ:OCS traded down $0.12 during trading on Friday, hitting $16.04. 32,043 shares of the company’s stock were exchanged, compared to its average volume of 37,117. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. Oculis has a 52-week low of $9.60 and a 52-week high of $18.00. The business’s 50-day simple moving average is $14.88 and its 200 day simple moving average is $12.86. The company has a market cap of $649.62 million, a price-to-earnings ratio of -8.37 and a beta of -0.16.

Oculis (NASDAQ:OCS) last released its earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. The business had revenue of $0.27 million for the quarter, compared to analysts’ expectations of $0.28 million. As a group, equities analysts predict that Oculis will post -2.09 EPS for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.